WO2003028802A2 - Devices for treating atrial fibrilation - Google Patents

Devices for treating atrial fibrilation Download PDF

Info

Publication number
WO2003028802A2
WO2003028802A2 PCT/US2002/031374 US0231374W WO03028802A2 WO 2003028802 A2 WO2003028802 A2 WO 2003028802A2 US 0231374 W US0231374 W US 0231374W WO 03028802 A2 WO03028802 A2 WO 03028802A2
Authority
WO
WIPO (PCT)
Prior art keywords
scaffold
heart
platform
platform scaffold
creating
Prior art date
Application number
PCT/US2002/031374
Other languages
French (fr)
Other versions
WO2003028802A3 (en
Inventor
John A. Macoviak
David A. Rahdert
Original Assignee
Am Discovery, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am Discovery, Incorporated filed Critical Am Discovery, Incorporated
Priority to US10/491,461 priority Critical patent/US20040243107A1/en
Priority to EP02800429A priority patent/EP1434621A2/en
Priority to PCT/US2002/031374 priority patent/WO2003028802A2/en
Priority to CA002462254A priority patent/CA2462254A1/en
Priority to AU2002362441A priority patent/AU2002362441A1/en
Publication of WO2003028802A2 publication Critical patent/WO2003028802A2/en
Publication of WO2003028802A3 publication Critical patent/WO2003028802A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/50—Supports for surgical instruments, e.g. articulated arms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
    • A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238—Type of minimally invasive operation
    • A61B2017/00243—Type of minimally invasive operation cardiac
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238—Type of minimally invasive operation
    • A61B2017/00243—Type of minimally invasive operation cardiac
    • A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22097—Valve removal in veins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320052—Guides for cutting instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345—Vascular system
    • A61B2018/00351—Heart
    • A61B2018/00392—Transmyocardial revascularisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2445—Annuloplasty rings in direct contact with the valve annulus

Definitions

  • This invention relates to methods and devices to improve the function of the heart. More particularly, the invention relates to methods and devices to treat atrial fibrillation.
  • Heart rhythm is normally established at a single point called the sinoatrial node, or SA node, located in the right atrium of the heart, near the opening of the superior vena cava.
  • SA node generates electrical impulses which spread throughout the heart and result in a rhythmic contraction of the heart, termed a sinus rhythm.
  • the SA node functions as a pacemaker for the heart.
  • a pacemaker other than the SA node is referred to as an ectopic pacemaker. Electrical signals from an ectopic pacemaker can disrupt a rhythmically contracting heart, resulting in an arrhythmia, characterized by a chaotic, disorganized heart rhythm. Fibrillation of the atria results in loss of atrial contraction and rapid impulses being sent to the ventricles causing high and irregular heart rates.
  • Atrial fibrillation is clinically related to several conditions, including anxiety, increased risk of stroke, reduced exercise tolerance, cardiomyopathy, congestive heart failure and decreased survival. Patients who experience AF are, generally, acutely aware of the symptoms. Current curative AF therapies are based upon a procedure that has become known as the
  • the Cox Maze procedure is an open-heart, surgical procedure that requires the patient to be placed on cardiopulmonary bypass equipment. The procedure requires six hours and the patient to be under general anesthesia. In this procedure, access to the heart is gained by way of a median sternotomy, which is a surgical split of the breast bone.
  • the left atrium is surgically incised along predetermined lines known to be effective in blocking the transmission of electrical signals from an ectopic pacemaker that triggers AF.
  • the incision lines create blocks that prevent conduction of unwanted electrical signals throughout the heart and permit a normal pattern of depolarization of the atria and ventricles beginning in the SA node and traveling to the AV or atrioventricular node.
  • the devices of the present invention form a platform, or scaffold for the precise delivery of various forms of energy for treatment of atrial fibrilation. Additionally, the devices of the present invention form a scaffold for the precise delivery of fluids to surrounding tissues. The use of additional energy sources can improve the delivery of various fluids into the surrounding tissue.
  • Figure 1 shows an embodiment of the invention in relation to its position within the heart, and within a patient's body.
  • Figure 2 shows an enlarged view of the device of Figure 1, with the loops surrounding the outlet of the pulmonary veins 210.
  • Figure 3 shows the reverse side of the device of Figures 1 and 2.
  • the reverse side's loop section 320 is shown having a multitude of holes, or micro-ports 330, that lie adjacent to the atrial walls.
  • Figure 4 shows an embodiment of the invention 400, in fluid communication with a catheter 410.
  • Figure 5 show an embodiment of the device shown in Figure 4.
  • Figure 6 is a frontal view of the device of Figures 4 and 5, with an additional positioning element.
  • Figure 7 is a longitudinal cross section of one embodiment of a tubule 720, having several micro-ports 730.
  • Figure 8 shows a radial cross section of the tubule shown in Figure 7.
  • Figures 9 and 10 show alternative tubule 910 designs, wherein the micro-ports are filled with porous plugs 920.
  • Figure 11 shows a catheter being introduced from the inferior vena cava 1110, into the right atrium 1140, through a septum 1120 between the right and left atrium, and into the left atrium 1150.
  • Figure 12 illustrates an embodiment of the invention 1200 that may be used to deliver energy to designated tissue.
  • FIG. 13 shows an embodiment of the invention, and the use of an energy source 1310 to deliver energy to devices of the present invention.
  • Figure 14 shows an embodiment of the invention 1400 having a positioning structure 1410 to standardize scaffold orientation within a treated heart chamber.
  • Figure 15 shows a scaffold in the form of a wire coil that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium in the example shown.
  • FIG 16 shows another embodiment for the scaffold 1600 of present invention.
  • the scaffold is in the form of a wire cage that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium.
  • Figure 17 shows another embodiment for the scaffold 1700 of present invention.
  • Figure 18 illustrates an alternative embodiment 1800 of the invention, positioned within the right atrium.
  • FIGS 19 through 22 show various embodiments of the invention having dual chamber structures.
  • Figures 23-25 show schematic views of a patient with a catheter 2340 being advanced from the inferior vena cava 2330, into the right atrium, and across the septum into the left atrium.
  • a second catheter 2320 is being advanced through the esophagus 2320.
  • Figure 1 shows an embodiment of the invention in relation to its position within the heart, and within a patient's body.
  • the device 100 is comprised of a platform, or scaffold that is shown being introduced from the inferior vena cava 150, into the right atrium 190, across the septum 115 between the right and left atrium, and into the left atrium 180.
  • the device 100 scaffold is shown having a right ablation loop 120, a left ablation loop 130, and an annular base 140.
  • the right and left ablation loops are shown to come within close proximity of the atrial walls that su ⁇ ound the pulmonary veins.
  • the pulmonary veins are common sources of ectopic pacemakers.
  • the device 100 is advanced through a catheter 110 and into position. Alternatively, the device 100 may be pre-loaded within a delivery catheter.
  • Figure 2 shows an enlarged view of the device of Figure 1, with the loops surrounding the outlet of the pulmonary veins 210.
  • the device may be used as a temporary platform, or scaffold, from which therapeutic fluids or energy can be deployed. Alternatively, the device may be left in place as a permanent implant.
  • the device 200 may have a gap of incomplete contact between the device and target tissue, the device is still effective, as described below, especially when used conjunction with tissue disrupting energies (electroporation or sonoporation), energies that promote fluid flow (electrophoresis or sonophoresis), and energies that promote scaffold vibrations.
  • tissue disrupting energies electroporation or sonoporation
  • energies that promote fluid flow electroporation or sonophoresis
  • energies that promote scaffold vibrations Many types of energies can be delivered to the scaffold either directly, or indirectly. Indirect application (using non-contact means) of energies can be applied trans-esophageally, trans- bronchially, trans-tracheally, trans-thoracically, across the sternum, etc.
  • Figure 3 shows the reverse side of the device of Figures 1 and 2.
  • the reverse side's loop section 320 is shown having a multitude of holes, or micro-ports 330, that lie adjacent to the atrial walls.
  • the micro-ports can be laser cut along the mural facing surface of the device.
  • the micro-ports direct fluids within the device to be released into adjacent tissues. Fluids within the device may include alcohol, potassium iodide, therapeutic drugs, etc.
  • the devices of the present invention may not have any micro-ports, and instead be used as a heat exchanger.
  • a heat removing fluid could be circulated within the device, thus giving rise to a temporary conduction block in the adjacent tissue.
  • the device 300 can be used a diagnostic tool, for determining the origin of ectopic pacemakers, for example.
  • the heat removal aspect of the device could result in permanent conduction block, tissue shrinkage (to tighten the skin, for promoting valve function, or close off an atrial appendage), etc.
  • the device's annular base 310 is positioned to surround the mitral annulus.
  • the loop section 320 is supported by upright members 315.
  • the loop section 320 is in fluid communication with the catheter via the inlet port 340.
  • this device may be used to prevent AF, but in a manner that differs from the Cox Maze procedure.
  • a specific pattern is cut into the heart to create a proper pathway for the signal generated from the SA node to travel throughout the heart.
  • the device shown differs in that it does not create a signal pathway, but rather isolates unwanted signals from propagating. The procedure is intended for use by an interventional electro- cardiologist, or other skilled professional.
  • Figure 4 shows an embodiment of the invention 400, in fluid communication with a catheter 410.
  • the catheter 410 may be introduced into the femoral vein, and advanced through the vena cava into the right atrium.
  • the catheter may be 12 to 14 French in diameter and approximately 150 centimeters long, depending on the dimensions of the patient's anatomy.
  • An exemplary catheter 410 is shown to have a guide wire port 420, a thru lumen port 430, and an ablation agent vent 440. Not shown is an ablation agent inlet port.
  • Preferred ablation agents are alcohol, or potassium iodide.
  • the catheter may be introduced into the patient under fluoroscopic guidance and advanced through the venous return to the right atrium of the heart. Using standard cardiology procedures, a trans-septal puncture will be performed and the catheter 410 may be advanced through the trans-septal puncture into the left atrium. Guide wires may be advanced into the atrial appendage, the mitral valve annulus and one of the pulmonary veins.
  • the device is preferably designed from a biocompatible, super-elastic material that will expand aggressively under the effects of body heat, or with the aid of an inflatable balloon. Under continued fluoroscopic guidance with the adjunctive capability for verification by intravascular ultrasound, the cardiologist will ensure that the device has expanded completely, and is positioned correctly and in close contact with surrounding heart wall.
  • Conduction block lines preferably fully transect the myocardium of the atrium (about 3 to 5 millimeters in thickness). Once the conduction block has been completed, the device may be removed from the patient.
  • FIG. 5 show an embodiment of the device shown in Figure 4.
  • the device is shown with an opposition member 540, a superior tubule 530 (superior relative to the pulmonary veins), and an inferior tubule 560 (inferior relative to the pulmonary veins).
  • the device can be designed with additional tubules to create additional lines of ablation, or additional opposition members.
  • the proximal end 520 of the device is positioned adjacent the trans-septal entry point.
  • the opposition member 540 is positioned along the anterior wall, opposite the pulmonary veins. The opposition member functions to transmit mural pressure from the atrium through the device to the tubules.
  • the superior tubule, 530 is positioned adjacent the apex of the left atrium.
  • the inferior tubule, 560 is positioned adjacent the base of the posterior wall.
  • the tubules, 530 and 560 have a multitude of micro-ports 500. The micro-ports allow a fluid to be released from inside the tubules and into the atrial walls.
  • the fluids released from the micro-ports located along the tubules create an electrical signal block.
  • the shape of signal block created by this embodiment is that of an oval, or a football.
  • the lines follow a path similar to two adjacent longitudinal lines on a world globe (turned sideways) beginning at the North Pole, and ending at the South Pole.
  • Figure 6 is a frontal view of the device of Figures 4 and 5.
  • An additional aspect of the device includes an orienting structure, so that the device takes advantage of anatomical features to achieve proper orientation within a heart chamber.
  • Figure 6 shows a circular structure 600 projecting from the distal end of the device. This circular projection may be positioned within an atrial appendage to aid with orientation of the device. This may be designed in the shaped of a pigtail, or corkscrew projecting from the distal end of the device.
  • Figure 7 is a longitudinal cross section of one embodiment of a tubule 720, having several micro-ports 730. The tubule 720 is encased within a sleeve 710.
  • a preferred sleeve 710 is a polymeric sleeve made from sintered gel.
  • the sleeve 710 functions as a diffusion barrier so that when fluid is released from the tubule 720, it is slowed down and allowed to diffuse into the adjacent atrial wall, rather than be released like a jet into the surrounding atrial wall.
  • the sleeve 710 also promotes an equal distribution of fluid throughout the tubule 720.
  • Figure 8 shows a radial cross section of the tubule shown in Figure 7.
  • Nitinol is a material that may be used for the tubule 720.
  • Figures 9 and 10 show alternative tubule 910 designs, wherein the micro-ports are filled with porous plugs 920.
  • a preferred porous plug 920 is comprised of sintered gel beads formed into a porous plug.
  • Figure 11 shows a catheter being introduced from the inferior vena cava 1110, into the right atrium 1140, through a septum 1120 between the right and left atrium, and into the left atrium 1150.
  • This figure illustrates a pump 1130 positioned within a catheter 1180.
  • the pump 1130 may be a piezoelectric pump used to drive fluid out through the micro-ports of the tubules.
  • Figure 12 illustrates an embodiment of the invention 1200 that may be used to deliver energy to designated tissue.
  • the device is shown connected to an energy component 1210 that may be a generator, defibrillator, pacemaker, or radio frequency device, that has been positioned underneath the skin (subclavian pocket) and that makes its way into the superior vena cava via the subclavian vein.
  • the device structure 1220 shown within the superior vena cava may function as a transformer, capacitor, or electrode.
  • Figure 13 shows an embodiment of the invention, and the use of an energy source 1310 to deliver energy to devices of the present invention.
  • the in-line member 1320 could be a transformer, capacitor, or electrode, depending on the need.
  • Figure 14 shows an embodiment of the invention 1400 having a positioning structure 1410 to standardize scaffold orientation within a treated heart chamber.
  • the positioning structure 1410 is shown being introduced to a pulmonary vein.
  • Figures 15 through 18 illustrate various embodiments of the invention.
  • Figure 15 shows a scaffold in the form of a wire coil that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium in the example shown.
  • the deployed scaffold has an approximately cylindrical configuration.
  • the wire coil of the scaffold may be constructed of a malleable or elastic biocompatible metal, such as stainless steel or a super-elastic or shape memory nickel/titanium alloy, for example.
  • the scaffold is sufficiently flexible such that it does not interfere with the normal contraction of the heart.
  • the wire coil may have a coating for improved biocompatibility, thermal and/or electrical insulation, etc.
  • FIG 16 shows another embodiment for the scaffold 1600 of present invention.
  • the scaffold is in the form of a wire cage that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium.
  • the deployed scaffold may have a dome-shaped or tapered cylindrical configuration, with an upper loop and a lower loop joined by longitudinal struts.
  • FIG 17 shows another embodiment for the scaffold 1700 of present invention.
  • the scaffold is in the form of a hoop-and-strut wire cage that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium.
  • the deployed scaffold may have a dome-shaped or tapered cylindrical configuration, with an upper hoop, a middle hoop and a lower hoop joined by longitudinal struts.
  • Figures 19 through 22 show various embodiments of the invention having dual chamber structures.
  • Figures 23-25 show schematic views of a patient with a catheter 2340 being advanced from the inferior vena cava 2330, into the right atrium, and across the septum into the left atrium.
  • a second catheter 2320 is being advanced through the esophagus 2320, and its close proximity to the left atrium makes it a suitable pathway for delivering a non-contact energy source, such as ultrasound (preferably low frequency ultrasound, below 1 MHz), radio frequency, or an inductive coupling mechanism.
  • Alternative non-contact energy source include microwaves. These energy sources can be applied to various devices to encourage the flow of ions in a prefe ⁇ ed direction, encourage fluid absorption, or cause ablation to occur.
  • ultrasound and other energy sources may be delivered to the devices of the present invention across the skin, transcutaneously. While the present invention has been described herein with respect to the exemplary embodiments and the best mode for practicing the invention it will become apparent to one of ordinary skill in the art that many modifications, improvements and sub combinations of the various embodiments, adaptations and variations can be made to the invention without departing from the spirit and scope thereof.

Abstract

The devices of the present invention form a platform, or scaffold for the precise delivery of various forms of energy for treatment of atrial fibrilation. Additionally, the devices of the present invention form a scaffold for the precise delivery of fluids to surrounding tissues. The use of additional energy sources can improve the delivery of various fluids into the surrounding tissue.

Description

METHODS AND DEVICES FOR TREATING ATRIAL FIBRILATION
REFERENCE TO PENDING PRIOR PATENT APPLICATION
This patent application claims benefit of pending prior U.S. Provisional Patent Application Serial Number 60/326,590 filed October 1, 2001 by John A. Macoviak, which patent is hereby incorporated by reference.
FIELD OF THE INVENTION
This invention relates to methods and devices to improve the function of the heart. More particularly, the invention relates to methods and devices to treat atrial fibrillation.
BACKGROUND OF THE INVENTION
To function properly as a pump, the heart must contract in a rhythmic pattern. Heart rhythm is normally established at a single point called the sinoatrial node, or SA node, located in the right atrium of the heart, near the opening of the superior vena cava. The SA node generates electrical impulses which spread throughout the heart and result in a rhythmic contraction of the heart, termed a sinus rhythm. Thus, the SA node functions as a pacemaker for the heart.
Other regions of the heart can potentially produce electrical impulses. A pacemaker other than the SA node is referred to as an ectopic pacemaker. Electrical signals from an ectopic pacemaker can disrupt a rhythmically contracting heart, resulting in an arrhythmia, characterized by a chaotic, disorganized heart rhythm. Fibrillation of the atria results in loss of atrial contraction and rapid impulses being sent to the ventricles causing high and irregular heart rates.
Atrial fibrillation (AF) is clinically related to several conditions, including anxiety, increased risk of stroke, reduced exercise tolerance, cardiomyopathy, congestive heart failure and decreased survival. Patients who experience AF are, generally, acutely aware of the symptoms. Current curative AF therapies are based upon a procedure that has become known as the
Cox Maze procedure. The Cox Maze procedure is an open-heart, surgical procedure that requires the patient to be placed on cardiopulmonary bypass equipment. The procedure requires six hours and the patient to be under general anesthesia. In this procedure, access to the heart is gained by way of a median sternotomy, which is a surgical split of the breast bone. The left atrium is surgically incised along predetermined lines known to be effective in blocking the transmission of electrical signals from an ectopic pacemaker that triggers AF. The incision lines create blocks that prevent conduction of unwanted electrical signals throughout the heart and permit a normal pattern of depolarization of the atria and ventricles beginning in the SA node and traveling to the AV or atrioventricular node.
Less invasive methods and devices for treating AF are needed that improve heart function and improve patient safety.
SUMMARY OF THE INVENTION
The devices of the present invention form a platform, or scaffold for the precise delivery of various forms of energy for treatment of atrial fibrilation. Additionally, the devices of the present invention form a scaffold for the precise delivery of fluids to surrounding tissues. The use of additional energy sources can improve the delivery of various fluids into the surrounding tissue.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows an embodiment of the invention in relation to its position within the heart, and within a patient's body.
Figure 2 shows an enlarged view of the device of Figure 1, with the loops surrounding the outlet of the pulmonary veins 210.
Figure 3 shows the reverse side of the device of Figures 1 and 2. The reverse side's loop section 320 is shown having a multitude of holes, or micro-ports 330, that lie adjacent to the atrial walls.
Figure 4 shows an embodiment of the invention 400, in fluid communication with a catheter 410.
Figure 5 show an embodiment of the device shown in Figure 4. Figure 6 is a frontal view of the device of Figures 4 and 5, with an additional positioning element.
Figure 7 is a longitudinal cross section of one embodiment of a tubule 720, having several micro-ports 730. Figure 8 shows a radial cross section of the tubule shown in Figure 7.
Figures 9 and 10 show alternative tubule 910 designs, wherein the micro-ports are filled with porous plugs 920.
Figure 11 shows a catheter being introduced from the inferior vena cava 1110, into the right atrium 1140, through a septum 1120 between the right and left atrium, and into the left atrium 1150.
Figure 12 illustrates an embodiment of the invention 1200 that may be used to deliver energy to designated tissue.
Figure 13 shows an embodiment of the invention, and the use of an energy source 1310 to deliver energy to devices of the present invention.
Figure 14 shows an embodiment of the invention 1400 having a positioning structure 1410 to standardize scaffold orientation within a treated heart chamber.
Figure 15 shows a scaffold in the form of a wire coil that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium in the example shown.
Figure 16 shows another embodiment for the scaffold 1600 of present invention. The scaffold is in the form of a wire cage that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium.
Figure 17 shows another embodiment for the scaffold 1700 of present invention. Figure 18 illustrates an alternative embodiment 1800 of the invention, positioned within the right atrium.
Figures 19 through 22 show various embodiments of the invention having dual chamber structures.
Figures 23-25 show schematic views of a patient with a catheter 2340 being advanced from the inferior vena cava 2330, into the right atrium, and across the septum into the left atrium. A second catheter 2320 is being advanced through the esophagus 2320.
DETAILED DESCRIPTION
Figure 1 shows an embodiment of the invention in relation to its position within the heart, and within a patient's body. The device 100 is comprised of a platform, or scaffold that is shown being introduced from the inferior vena cava 150, into the right atrium 190, across the septum 115 between the right and left atrium, and into the left atrium 180. The device 100 scaffold is shown having a right ablation loop 120, a left ablation loop 130, and an annular base 140. The right and left ablation loops are shown to come within close proximity of the atrial walls that suπound the pulmonary veins. The pulmonary veins are common sources of ectopic pacemakers. The device 100 is advanced through a catheter 110 and into position. Alternatively, the device 100 may be pre-loaded within a delivery catheter.
Figure 2 shows an enlarged view of the device of Figure 1, with the loops surrounding the outlet of the pulmonary veins 210. The device may be used as a temporary platform, or scaffold, from which therapeutic fluids or energy can be deployed. Alternatively, the device may be left in place as a permanent implant.
Although the device 200 may have a gap of incomplete contact between the device and target tissue, the device is still effective, as described below, especially when used conjunction with tissue disrupting energies (electroporation or sonoporation), energies that promote fluid flow (electrophoresis or sonophoresis), and energies that promote scaffold vibrations. Many types of energies can be delivered to the scaffold either directly, or indirectly. Indirect application (using non-contact means) of energies can be applied trans-esophageally, trans- bronchially, trans-tracheally, trans-thoracically, across the sternum, etc.
Figure 3 shows the reverse side of the device of Figures 1 and 2. The reverse side's loop section 320 is shown having a multitude of holes, or micro-ports 330, that lie adjacent to the atrial walls. The micro-ports can be laser cut along the mural facing surface of the device. The micro-ports direct fluids within the device to be released into adjacent tissues. Fluids within the device may include alcohol, potassium iodide, therapeutic drugs, etc.
Alternatively, the devices of the present invention may not have any micro-ports, and instead be used as a heat exchanger. For example, a heat removing fluid could be circulated within the device, thus giving rise to a temporary conduction block in the adjacent tissue. As such, the device 300 can be used a diagnostic tool, for determining the origin of ectopic pacemakers, for example. Also, with longer exposures to adjacent tissues, the heat removal aspect of the device could result in permanent conduction block, tissue shrinkage (to tighten the skin, for promoting valve function, or close off an atrial appendage), etc. When used in the left atrium, the device's annular base 310 is positioned to surround the mitral annulus. The loop section 320 is supported by upright members 315. The loop section 320 is in fluid communication with the catheter via the inlet port 340. As shown, this device may be used to prevent AF, but in a manner that differs from the Cox Maze procedure. In the Cox Maze procedure, a specific pattern is cut into the heart to create a proper pathway for the signal generated from the SA node to travel throughout the heart. The device shown differs in that it does not create a signal pathway, but rather isolates unwanted signals from propagating. The procedure is intended for use by an interventional electro- cardiologist, or other skilled professional.
Figure 4 shows an embodiment of the invention 400, in fluid communication with a catheter 410. The catheter 410 may be introduced into the femoral vein, and advanced through the vena cava into the right atrium. The catheter may be 12 to 14 French in diameter and approximately 150 centimeters long, depending on the dimensions of the patient's anatomy. An exemplary catheter 410 is shown to have a guide wire port 420, a thru lumen port 430, and an ablation agent vent 440. Not shown is an ablation agent inlet port. Preferred ablation agents are alcohol, or potassium iodide.
The catheter may be introduced into the patient under fluoroscopic guidance and advanced through the venous return to the right atrium of the heart. Using standard cardiology procedures, a trans-septal puncture will be performed and the catheter 410 may be advanced through the trans-septal puncture into the left atrium. Guide wires may be advanced into the atrial appendage, the mitral valve annulus and one of the pulmonary veins. The device is preferably designed from a biocompatible, super-elastic material that will expand aggressively under the effects of body heat, or with the aid of an inflatable balloon. Under continued fluoroscopic guidance with the adjunctive capability for verification by intravascular ultrasound, the cardiologist will ensure that the device has expanded completely, and is positioned correctly and in close contact with surrounding heart wall. The device is then used as a platform for the delivery of energy or a fluid that can create a conduction block, or be used diagnostically. Conduction block lines preferably fully transect the myocardium of the atrium (about 3 to 5 millimeters in thickness). Once the conduction block has been completed, the device may be removed from the patient.
The benefits of using alcohol, or other tissue fixative agents, is the drastic reduction of energy required to create conduction block, resulting in a safer and more effective ablation because the tissue is in fact toughened by the fixative properties of alcohol-like agents that cause a coagulation cellular necrosis instead of a weakened tissue wall liquefaction necrosis that is caused with other types of energy to create conduction block. Figure 5 show an embodiment of the device shown in Figure 4. The device is shown with an opposition member 540, a superior tubule 530 (superior relative to the pulmonary veins), and an inferior tubule 560 (inferior relative to the pulmonary veins). In addition, the device can be designed with additional tubules to create additional lines of ablation, or additional opposition members. Assuming a trans-septal introduction of this embodiment from the right atrium into the left atrium, the proximal end 520 of the device is positioned adjacent the trans-septal entry point. The opposition member 540 is positioned along the anterior wall, opposite the pulmonary veins. The opposition member functions to transmit mural pressure from the atrium through the device to the tubules. The superior tubule, 530, is positioned adjacent the apex of the left atrium. The inferior tubule, 560, is positioned adjacent the base of the posterior wall. The tubules, 530 and 560, have a multitude of micro-ports 500. The micro-ports allow a fluid to be released from inside the tubules and into the atrial walls. Several fluids can be used, any of which function to disrupt the flow of unwanted electrical signals. Thus, the fluids released from the micro-ports located along the tubules create an electrical signal block. The shape of signal block created by this embodiment is that of an oval, or a football. The lines follow a path similar to two adjacent longitudinal lines on a world globe (turned sideways) beginning at the North Pole, and ending at the South Pole.
Figure 6 is a frontal view of the device of Figures 4 and 5. An additional aspect of the device includes an orienting structure, so that the device takes advantage of anatomical features to achieve proper orientation within a heart chamber. For example, Figure 6 shows a circular structure 600 projecting from the distal end of the device. This circular projection may be positioned within an atrial appendage to aid with orientation of the device. This may be designed in the shaped of a pigtail, or corkscrew projecting from the distal end of the device. Figure 7 is a longitudinal cross section of one embodiment of a tubule 720, having several micro-ports 730. The tubule 720 is encased within a sleeve 710. A preferred sleeve 710 is a polymeric sleeve made from sintered gel. The sleeve 710, functions as a diffusion barrier so that when fluid is released from the tubule 720, it is slowed down and allowed to diffuse into the adjacent atrial wall, rather than be released like a jet into the surrounding atrial wall. The sleeve 710 also promotes an equal distribution of fluid throughout the tubule 720. Figure 8 shows a radial cross section of the tubule shown in Figure 7. Nitinol is a material that may be used for the tubule 720. Figures 9 and 10 show alternative tubule 910 designs, wherein the micro-ports are filled with porous plugs 920. A preferred porous plug 920 is comprised of sintered gel beads formed into a porous plug.
Figure 11 shows a catheter being introduced from the inferior vena cava 1110, into the right atrium 1140, through a septum 1120 between the right and left atrium, and into the left atrium 1150. This figure illustrates a pump 1130 positioned within a catheter 1180. Also, there is a guide wire 1170 shown protruding from the distal end of the catheter 1180. The pump 1130 may be a piezoelectric pump used to drive fluid out through the micro-ports of the tubules. In another embodiment, there may be no in-line pump. Instead, an outside pump may be used. Figure 12 illustrates an embodiment of the invention 1200 that may be used to deliver energy to designated tissue. The device is shown connected to an energy component 1210 that may be a generator, defibrillator, pacemaker, or radio frequency device, that has been positioned underneath the skin (subclavian pocket) and that makes its way into the superior vena cava via the subclavian vein. The device structure 1220 shown within the superior vena cava may function as a transformer, capacitor, or electrode.
Figure 13 shows an embodiment of the invention, and the use of an energy source 1310 to deliver energy to devices of the present invention. The in-line member 1320 could be a transformer, capacitor, or electrode, depending on the need.
Figure 14 shows an embodiment of the invention 1400 having a positioning structure 1410 to standardize scaffold orientation within a treated heart chamber. In this embodiment, the positioning structure 1410 is shown being introduced to a pulmonary vein.
Figures 15 through 18 illustrate various embodiments of the invention. Figure 15 shows a scaffold in the form of a wire coil that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium in the example shown. The deployed scaffold has an approximately cylindrical configuration. The wire coil of the scaffold may be constructed of a malleable or elastic biocompatible metal, such as stainless steel or a super-elastic or shape memory nickel/titanium alloy, for example. Preferably, the scaffold is sufficiently flexible such that it does not interfere with the normal contraction of the heart. In addition, the wire coil may have a coating for improved biocompatibility, thermal and/or electrical insulation, etc.
Figure 16 shows another embodiment for the scaffold 1600 of present invention. The scaffold is in the form of a wire cage that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium. The deployed scaffold may have a dome-shaped or tapered cylindrical configuration, with an upper loop and a lower loop joined by longitudinal struts.
Figure 17 shows another embodiment for the scaffold 1700 of present invention. The scaffold is in the form of a hoop-and-strut wire cage that, when deployed, closely conforms to the interior of a patient's heart chamber, such as the patient's left atrium. The deployed scaffold may have a dome-shaped or tapered cylindrical configuration, with an upper hoop, a middle hoop and a lower hoop joined by longitudinal struts.
Figures 19 through 22 show various embodiments of the invention having dual chamber structures. Figures 23-25 show schematic views of a patient with a catheter 2340 being advanced from the inferior vena cava 2330, into the right atrium, and across the septum into the left atrium. A second catheter 2320 is being advanced through the esophagus 2320, and its close proximity to the left atrium makes it a suitable pathway for delivering a non-contact energy source, such as ultrasound (preferably low frequency ultrasound, below 1 MHz), radio frequency, or an inductive coupling mechanism. Alternative non-contact energy source include microwaves. These energy sources can be applied to various devices to encourage the flow of ions in a prefeπed direction, encourage fluid absorption, or cause ablation to occur. Also, ultrasound and other energy sources may be delivered to the devices of the present invention across the skin, transcutaneously. While the present invention has been described herein with respect to the exemplary embodiments and the best mode for practicing the invention it will become apparent to one of ordinary skill in the art that many modifications, improvements and sub combinations of the various embodiments, adaptations and variations can be made to the invention without departing from the spirit and scope thereof.

Claims

We claim:
1. A platform scaffold for treating atrial fibrilation, the platform scaffold comprising: an annular base, a tubular loop section, upright members, and an inlet port, wherein the annular base supports the loop section via the upright members, and the inlet port enables communication with other devices.
2. The platform scaffold of claim 1, further comprising micro-ports positioned along the heart wall contacting surface of the tubular loop section.
3. The platform scaffold of claim 2, wherein the micro-ports are filled with porous plugs.
4. The platform scaffold of claim 1, wherein the platform scaffold is manufactured from a super-elastic material.
5. The platform scaffold of claim 1, wherein the tubular loop section is encased within a polymeric sleeve.
6. A platform scaffold for treating atrial fibrilation, the platform scaffold comprising: a first structural rail, a second therapeutic rail, and a third therapeutic rail, wherein the rails originate at a first point, and terminate at a second point, and expand radially away from the first point, and contract radially toward the second point, and when placed within a heart chamber, the first structural member transmits force from the suπounding heart wall to the second and third therapeutic rails to ensure all rails contact the adjacent heart wall.
7. The second and third therapeutic rails of claim 6, further comprising micro-ports positioned along the heart wall contacting surface of the rails.
8. The second and third therapeutic rails of claim 7, wherein the micro-ports are filled with porous plugs.
9. The platform scaffold claim 6, wherein the platform scaffold is manufactured from a super-elastic material.
10. The platform scaffold of claim 6, wherein the rails are encased within a polymeric sleeve.
11. The platform scaffold of claim 6, further comprising a positioning member to standardize scaffold orientation within a treated heart chamber.
12. A platform scaffold for treating atrial fibrilation, comprising: a wire, the wire having an approximately cylindrical configuration when deployed closely conforming to the interior of a patient's heart chamber.
13. The platform scaffold of claim 12, wherein the platform scaffold is manufactured from a super-elastic material.
14. A platform scaffold for treating atrial fibrilation, comprising: a wire form birdcage, the wire form birdcage having a dome-shaped or tapered cylindrical configuration, with an upper loop and a lower loop joined by longitudinal struts, the wire form birdcage closely conforming to the interior of a patient's heart chamber.
15. The platform scaffold of claim 14, wherein the platform scaffold is manufactured from a super-elastic material.
16. A platform scaffold for treating atrial fibrilation, comprising: a wire form hoop-and-strut wire cage, the wire form hoop-and-strut wire cage having a dome-shaped or tapered cylindrical configuration, with an upper hoop, a middle hoop and a lower hoop joined by longitudinal struts, the wire form hoop-and-strut wire cage closely conforming to the interior of a patient's heart chamber.
17. The platform scaffold of claim 16, wherein the platform scaffold is manufactured from a super-elastic material.
18. A method of diagnosing signal conduction within the heart comprising: transvascularly introducing a platform scaffold into the heart; positioning the platform scaffold; releasing a heat absorbing fluid into the platform scaffold, the heat absorbing fluid them passing through the platform scaffold; and observing the effect of localized cooling on the heart to temporarily interrupt signal conduction.
19. A method of creating a signal block within the heart comprising: transvascularly introducing a platform scaffold into the heart having micro-ports; positioning the platform scaffold; and releasing a tissue fixative fluid into the scaffold, the tissue fixative fluid then passing through the platform scaffold.
20. The method of creating a signal block within the heart of claim 19, further comprising the step of applying tissue disrupting energies that promote fluid flow.
21. The method of creating a signal block within the heart of claim 20, wherein the tissue disrupting energy may be applied directly to the scaffold.
22. The method of creating a signal block within the heart of claim 20, wherein the tissue disrupting energy may be applied indirectly to the scaffold.
23. The method of creating a signal block within the heart of claim 19, further comprising the step of applying energies that promote scaffold vibrations.
24. The method of creating a signal block within the heart of claim 23, wherein the energies that promote scaffold vibrations may be applied directly to the scaffold.
25. The method of creating a signal block within the heart of claim 23, wherein the energies that promote scaffold vibrations may be applied indirectly to the scaffold.
26. A method of creating a signal block within the heart comprising: transvascularly introducing a platform scaffold into the heart; positioning the platform scaffold; and transferring energy to the scaffold to create lines of ablation.
27. The method of creating a signal block within the heart of claim 26, wherein the energies that creates lines of ablation may be applied directly to the scaffold.
28. The method of creating a signal block within the heart of claim 26, wherein the energies that create lines of ablation may be applied indirectly to the scaffold.
PCT/US2002/031374 2001-10-01 2002-10-01 Devices for treating atrial fibrilation WO2003028802A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/491,461 US20040243107A1 (en) 2001-10-01 2002-10-01 Methods and devices for treating atrial fibrilation
EP02800429A EP1434621A2 (en) 2001-10-01 2002-10-01 Devices for treating atrial fibrilation
PCT/US2002/031374 WO2003028802A2 (en) 2001-10-01 2002-10-01 Devices for treating atrial fibrilation
CA002462254A CA2462254A1 (en) 2001-10-01 2002-10-01 Devices for treating atrial fibrilation
AU2002362441A AU2002362441A1 (en) 2001-10-01 2002-10-01 Devices for treating atrial fibrilation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/326,590 2001-10-01
PCT/US2002/031374 WO2003028802A2 (en) 2001-10-01 2002-10-01 Devices for treating atrial fibrilation

Publications (2)

Publication Number Publication Date
WO2003028802A2 true WO2003028802A2 (en) 2003-04-10
WO2003028802A3 WO2003028802A3 (en) 2003-08-07

Family

ID=39885038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031374 WO2003028802A2 (en) 2001-10-01 2002-10-01 Devices for treating atrial fibrilation

Country Status (2)

Country Link
EP (1) EP1434621A2 (en)
WO (1) WO2003028802A2 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1602339A1 (en) * 2004-04-01 2005-12-07 A M Discovery, Inc. Devices, systems, and methods for treating atrial fibrillation
WO2010081041A1 (en) * 2009-01-08 2010-07-15 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9072527B2 (en) 2002-04-08 2015-07-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatuses and methods for renal neuromodulation
US9265558B2 (en) 2002-04-08 2016-02-23 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9649115B2 (en) 2009-06-17 2017-05-16 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9675413B2 (en) 2002-04-08 2017-06-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9693780B2 (en) 2009-06-17 2017-07-04 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9693781B2 (en) 2009-06-17 2017-07-04 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9707035B2 (en) 2002-04-08 2017-07-18 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9743983B2 (en) 2002-04-08 2017-08-29 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US9757193B2 (en) 2002-04-08 2017-09-12 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatus for renal neuromodulation
US9795387B2 (en) 1997-05-19 2017-10-24 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9827040B2 (en) 2002-04-08 2017-11-28 Medtronic Adrian Luxembourg S.a.r.l. Methods and apparatus for intravascularly-induced neuromodulation
US9950161B2 (en) 2004-10-05 2018-04-24 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US9968611B2 (en) 2002-04-08 2018-05-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10034708B2 (en) 2002-04-08 2018-07-31 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for thermally-induced renal neuromodulation
US10039596B2 (en) 2002-04-08 2018-08-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatus for renal neuromodulation via an intra-to-extravascular approach
US10064628B2 (en) 2009-06-17 2018-09-04 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10080864B2 (en) 2012-10-19 2018-09-25 Medtronic Ardian Luxembourg S.A.R.L. Packaging for catheter treatment devices and associated devices, systems, and methods
US10124195B2 (en) 2002-04-08 2018-11-13 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermally-induced renal neuromodulation
US10130792B2 (en) 2002-04-08 2018-11-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs
US10179020B2 (en) 2010-10-25 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10537385B2 (en) 2008-12-31 2020-01-21 Medtronic Ardian Luxembourg S.A.R.L. Intravascular, thermally-induced renal neuromodulation for treatment of polycystic ovary syndrome or infertility
US10631969B2 (en) 2009-06-17 2020-04-28 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10772637B2 (en) 2009-06-17 2020-09-15 Coherex Medical, Inc. Medical device and delivery system for modification of left atrial appendage and methods thereof
US10874455B2 (en) 2012-03-08 2020-12-29 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US11338140B2 (en) 2012-03-08 2022-05-24 Medtronic Ardian Luxembourg S.A.R.L. Monitoring of neuromodulation using biomarkers
US11369355B2 (en) 2019-06-17 2022-06-28 Coherex Medical, Inc. Medical device and system for occluding a tissue opening and method thereof
US11812969B2 (en) 2020-12-03 2023-11-14 Coherex Medical, Inc. Medical device and system for occluding a tissue opening and method thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5263977A (en) * 1992-10-26 1993-11-23 Angeion Corporation Electrode spacing device
DE10032000A1 (en) * 1999-07-01 2001-01-25 Medtronic Inc System for electrophoretic delivery of therapeutic substance to internal bodily tissues, includes electrode with insulation, biocompatible matrix and second electrode

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5263977A (en) * 1992-10-26 1993-11-23 Angeion Corporation Electrode spacing device
DE10032000A1 (en) * 1999-07-01 2001-01-25 Medtronic Inc System for electrophoretic delivery of therapeutic substance to internal bodily tissues, includes electrode with insulation, biocompatible matrix and second electrode

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795387B2 (en) 1997-05-19 2017-10-24 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10179027B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable baskets for renal neuromodulation and associated systems and methods
US10441356B2 (en) 2002-04-08 2019-10-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation via neuromodulatory agents
US9675413B2 (en) 2002-04-08 2017-06-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US10130792B2 (en) 2002-04-08 2018-11-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs
US10179235B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US9072527B2 (en) 2002-04-08 2015-07-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatuses and methods for renal neuromodulation
US10272246B2 (en) 2002-04-08 2019-04-30 Medtronic Adrian Luxembourg S.a.r.l Methods for extravascular renal neuromodulation
US11033328B2 (en) 2002-04-08 2021-06-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US10850091B2 (en) 2002-04-08 2020-12-01 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US9731132B2 (en) 2002-04-08 2017-08-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US9743983B2 (en) 2002-04-08 2017-08-29 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US10179028B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating patients via renal neuromodulation
US9757193B2 (en) 2002-04-08 2017-09-12 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatus for renal neuromodulation
US9757192B2 (en) 2002-04-08 2017-09-12 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US9265558B2 (en) 2002-04-08 2016-02-23 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US9814873B2 (en) 2002-04-08 2017-11-14 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US9827040B2 (en) 2002-04-08 2017-11-28 Medtronic Adrian Luxembourg S.a.r.l. Methods and apparatus for intravascularly-induced neuromodulation
US9827041B2 (en) 2002-04-08 2017-11-28 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatuses for renal denervation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US10245429B2 (en) 2002-04-08 2019-04-02 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9895195B2 (en) 2002-04-08 2018-02-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9907611B2 (en) 2002-04-08 2018-03-06 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US10293190B2 (en) 2002-04-08 2019-05-21 Medtronic Ardian Luxembourg S.A.R.L. Thermally-induced renal neuromodulation and associated systems and methods
US9956410B2 (en) 2002-04-08 2018-05-01 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9968611B2 (en) 2002-04-08 2018-05-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US10420606B2 (en) 2002-04-08 2019-09-24 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US10034708B2 (en) 2002-04-08 2018-07-31 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for thermally-induced renal neuromodulation
US10039596B2 (en) 2002-04-08 2018-08-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatus for renal neuromodulation via an intra-to-extravascular approach
US10376312B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for monopolar renal neuromodulation
US10376516B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US10376311B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravascularly-induced neuromodulation
US10105180B2 (en) 2002-04-08 2018-10-23 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravascularly-induced neuromodulation
US10111707B2 (en) 2002-04-08 2018-10-30 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of human patients
US10124195B2 (en) 2002-04-08 2018-11-13 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermally-induced renal neuromodulation
US9707035B2 (en) 2002-04-08 2017-07-18 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
EP1602339A1 (en) * 2004-04-01 2005-12-07 A M Discovery, Inc. Devices, systems, and methods for treating atrial fibrillation
US9950161B2 (en) 2004-10-05 2018-04-24 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US10537734B2 (en) 2004-10-05 2020-01-21 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US11154303B2 (en) 2007-10-19 2021-10-26 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10561460B2 (en) 2008-12-31 2020-02-18 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation systems and methods for treatment of sexual dysfunction
US10537385B2 (en) 2008-12-31 2020-01-21 Medtronic Ardian Luxembourg S.A.R.L. Intravascular, thermally-induced renal neuromodulation for treatment of polycystic ovary syndrome or infertility
US10420564B2 (en) 2009-01-08 2019-09-24 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US8840641B2 (en) 2009-01-08 2014-09-23 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10695070B2 (en) 2009-01-08 2020-06-30 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
WO2010081041A1 (en) * 2009-01-08 2010-07-15 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9750505B2 (en) 2009-01-08 2017-09-05 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10076337B2 (en) 2009-06-17 2018-09-18 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10582930B2 (en) 2009-06-17 2020-03-10 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10064628B2 (en) 2009-06-17 2018-09-04 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9883864B2 (en) 2009-06-17 2018-02-06 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9649115B2 (en) 2009-06-17 2017-05-16 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10537332B2 (en) 2009-06-17 2020-01-21 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9693781B2 (en) 2009-06-17 2017-07-04 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US11540837B2 (en) 2009-06-17 2023-01-03 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10582929B2 (en) 2009-06-17 2020-03-10 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US11253262B2 (en) 2009-06-17 2022-02-22 Coherex Medical, Inc. Delivery device, system, and method thereof
US10631969B2 (en) 2009-06-17 2020-04-28 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US11000289B2 (en) 2009-06-17 2021-05-11 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10758240B2 (en) 2009-06-17 2020-09-01 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10772637B2 (en) 2009-06-17 2020-09-15 Coherex Medical, Inc. Medical device and delivery system for modification of left atrial appendage and methods thereof
US9693780B2 (en) 2009-06-17 2017-07-04 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US11918227B2 (en) 2009-06-17 2024-03-05 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US10179020B2 (en) 2010-10-25 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US10874455B2 (en) 2012-03-08 2020-12-29 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US11338140B2 (en) 2012-03-08 2022-05-24 Medtronic Ardian Luxembourg S.A.R.L. Monitoring of neuromodulation using biomarkers
US10080864B2 (en) 2012-10-19 2018-09-25 Medtronic Ardian Luxembourg S.A.R.L. Packaging for catheter treatment devices and associated devices, systems, and methods
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US11369355B2 (en) 2019-06-17 2022-06-28 Coherex Medical, Inc. Medical device and system for occluding a tissue opening and method thereof
US11812969B2 (en) 2020-12-03 2023-11-14 Coherex Medical, Inc. Medical device and system for occluding a tissue opening and method thereof

Also Published As

Publication number Publication date
WO2003028802A3 (en) 2003-08-07
EP1434621A2 (en) 2004-07-07

Similar Documents

Publication Publication Date Title
US20040243107A1 (en) Methods and devices for treating atrial fibrilation
CA2462254A1 (en) Devices for treating atrial fibrilation
EP1434621A2 (en) Devices for treating atrial fibrilation
KR102053451B1 (en) Cerclage atrial implantable cardioverter defibrillators
US6925327B2 (en) Pulmonary vein arrhythmia diagnostic device and method for use
EP2362798B1 (en) Shockwave valvuloplasty catheter system
US5104393A (en) Catheter
US9039594B2 (en) Signal transmitting and lesion excluding heart implants for pacing, defibrillating, and/or sensing of heart beat
US7493162B2 (en) Pulmonary vein stent for treating atrial fibrillation
US6306133B1 (en) Ablation catheter system and methods for repairing a valvular annulus
RU2372052C2 (en) Device, kit and method for treating disturbances of heart rhythm regulation system
JP4786710B2 (en) Tools and kits for the treatment of disorders in the heart rate regulation system
EP1602339A1 (en) Devices, systems, and methods for treating atrial fibrillation
US20120290024A1 (en) Transvenous renal nerve modulation for treatment of hypertension, cardiovascular disorders, and chronic renal diseases
US20120290053A1 (en) Renal nerve stimulation lead, delivery system, and method
JP2008540052A (en) Body cavity shaping device with cardiac leads
WO2007022519A2 (en) Steerable heart implants for congestive heart failure
US20050021091A1 (en) System for the delivery of a biologic therapy with device monitoring and back-up
US20120271340A1 (en) Method and Apparatus for Embolic Protection During Heart Procedure
JP2022543873A (en) Cardiac annuloplasty and pacing procedures, related devices and methods
US20120271341A1 (en) Method and Apparatus for Treating a Mitral Valve Prolapse and Providing Embolic Protection
Wieberdink Experimental production of permanent heart block (total or bundle branch block) without circulatory arrest or extracorporeal circulation.
EP3884993A1 (en) Device for valve regurgitation surgery and cardiac pacemaker lead fixation
Burger et al. Device Therapy of Rhythm Disorders
KR20090013189A (en) A controllable device, a kit and a method for treatment of disorders in the heart rhythm regulation system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2462254

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002800429

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10491461

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002800429

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002800429

Country of ref document: EP